CDX2 and adenocarcinoma: A retrospective study focusing on unfavorable subgroup adenocarcinomas with gastrointestinal features (CK7+/CK20-/any CDX2 OR CK7-/CK20+/CDX2- OR CK7-/CK20-/CDX2+) reported a median overall survival (OS) of just 11.8 months.